◆ NeutralIPSEY
IPSEN - Buy-back programme - Art 5 of MAR - Week 28 - 2026
GlobeNewswire Inc.·
Ipsen conducted share repurchases totaling 28,541 shares between July 6-10, 2026, at an average price of €166.05. The company announced that Dysport (botulinum toxin) achieved positive Phase III results in both episodic and chronic migraine trials, becoming the first botulinum toxin to meet primary endpoints in both indications.
Read Full Article at GlobeNewswire Inc. →